Renal Cell Carcinoma treatment has been redefined by immunotherapy. Checkpoint inhibitors (PD-1 / CTLA-4) used in combination have significantly outperformed older Tyrosine Kinase Inhibitors (TKI) monotherapy protocols.
PHARMACOLOGY
• Oct 18, 2023
Immunotherapy in Stage IV Renal Cell Carcinoma
Dr. Michael Vane
Clinical Oncologist & Researcher
Immunotherapy in Stage IV Renal Cell Carcinoma
Discussion (12)
verified
Verified Students Only
Join the Academic Debate
This section is reserved for verified medical professionals and students. Sign in to contribute your clinical insights.
Sign In to CommentJD
Dr. John Doe (Cardiology Resident)
2h ago
Exceptional summary of the current landscape. One question: did the study account for patients with existing comorbidities like diabetes which might affect stem cell efficacy?
Related Modules
NEUROLOGY
Advancements in Minimally Invasive Robotic Neurosurgery
A comprehensive clinical review of the latest tactile-feedback systems in neurosurgical robotics and their impact on patient recovery times in tertiary care settings.
CARDIOLOGY
Novel Approaches to Heart Failure Management
Recent clinical trials suggest a shift towards quad-therapy protocols earlier in the diagnosis phase of heart failure with reduced ejection fraction.